东阳光集团广东东莞总部 ...

Core Viewpoint - Dongyangguang Group is entering a new development stage with the upcoming IPO of Dongyangguang Pharmaceutical, marking a significant step in China's innovative pharmaceutical sector [1][5]. Group Overview - Established 28 years ago, Dongyangguang Group has grown from scratch to a private enterprise with over 30,000 employees and assets exceeding 80 billion yuan, becoming a leader in multiple industries including electronic new materials, biomedicine, and health care [1][2]. - The company has successfully cultivated two publicly listed companies with market capitalizations in the hundred billion range [1]. Industry Development - The group is actively expanding into the artificial intelligence and robotics sectors, recognizing the potential of AI as a new engine for high-quality development [2][3]. - Dongyangguang has established a complete fluorine and chlorine chemical industry chain, positioning itself as the only company in South China with such capabilities [4]. Pharmaceutical Sector - Dongyangguang Pharmaceutical has 150 globally approved drugs and over 100 in the pipeline, aiming to become a leading pharmaceutical enterprise in China and globally [5][6]. - The company has established a robust R&D system and has been recognized for its innovation, winning multiple awards and holding over 2,500 patents [6][11]. Health and Wellness Industry - The company has pioneered the ecological breeding of Cordyceps sinensis, achieving significant production milestones and aiming for an annual output of 100 tons with sales exceeding 10 billion yuan [7][8]. - Dongyangguang is developing a product matrix around Cordyceps, targeting the burgeoning health and wellness market [8]. Innovation and Internationalization - The group emphasizes innovation and internationalization as core strategies, having built a strong R&D platform and established a global sales network covering eight countries [9][12]. - Dongyangguang has made significant investments in R&D, including collaborations with international experts and institutions to enhance its competitive edge [11][12]. Social Responsibility - Dongyangguang Group has committed over 500 million yuan to public welfare and has created over 10,000 job opportunities, reflecting its dedication to social responsibility [14].

广东东阳光科技控股股份有限公司 关于控股股东之一致行动人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 证券代码：600673 证券简称：东阳光 编号：临2025-49号 重要内容提示: 债券代码：242444 债券简称：25东科01 ● 控股股东之一致行动人宜昌东阳光药业股份有限公司（以下简称"宜昌药业股份"）持有本公司股份 545,023,350股，占公司总股本的18.11%；截至本次股份质押完成后，宜昌药业股份持有本公司股份累 计质押数量531,500,000股，占其持股数量的97.52%。 截至本公告披露日，深圳东阳光实业及其一致行动人累计质押股份情况如下： ■ 三、上市公司控股股东股份质押情况 1、控股股东深圳东阳光实业未来半年内将到期的质押股份数量累计8,678.94万股，占其所持股份的 14.05%，占公司总股本的2.88%，对应融资余额102,499.70万元；一年内将到期的质押股份数量累计 28,258.94万股，占其所持股份的45.75%，占公司总股本的9.39%，对应融资余额505,0 ...

| 证券代码：600673 | 证券简称：东阳光 | | 编号：临 | 2025-49 号 | | --- | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 东科 | 01 | | | 截至本公告披露日，公司控股股东累计质押股数数量为 551,798,054 股， 占其持股数量的 89.34%；控股股东及其一致行动人累计质押股数数量为 1,264,388,597 股，占合计持股数量比例为 79.62%。 一、本次股份质押基本情况 广东东阳光科技控股股份有限公司（以下简称"公司"）于近日收到控股股 东之一致行动人宜昌药业股份的通知，获悉其将其持有的公司部分无限售流通股 进行了质押，具体事项如下： | 股东名称 | 是否 为控 | 本次质押股数 | 是否 | 是否 | | | | | 占其所 | 占公司 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 为限 | 补充 | 质押起始日 | | 质押到期日 | 质权人 | 持股份 | 总股本 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日综合板块主力资金净流出1.14亿元，游资资金净流入4390.61万元，散户资金净 流入6996.74万元。综合板块个股资金流向见下表： 证券之星消息，7月30日综合板块较上一交易日下跌1.08%，东阳光领跌。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。综合板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600689 | 上海三毛 | 12.58 | 1.53% | 4.87万 | 6053.67万 | | 000523 | 红棉股份 | 3.36 | 1.20% | 28.99万 | 9701.31万 | | 000652 | 泰达股份 | 4.51 | 0.89% | 26.46万 | 1.19亿 | | 000753 | 漳州发展 | 5.69 | 0.89% | 37. ...

Group 1 - The core viewpoint of the news is that Dongyangguang Changjiang Pharmaceutical Co., Ltd. is set to complete its last trading day on the Hong Kong Stock Exchange and will officially list as "Dongyangguang Pharmaceutical" on August 7, marking a significant innovation in the capital market with its "H-share absorption merger and introduction listing" model [1] - The company aims to achieve overall listing by merging its Hong Kong-listed subsidiary, Dongyangguang Changjiang Pharmaceutical, into its parent company, Dongyangguang Pharmaceutical, and issuing H-shares to minority shareholders of the subsidiary [1] - This move is seen as a way to break traditional capital operation barriers, reduce financial friction costs associated with acquisitions, and ensure shareholder rights, providing a reference model for industrial integration and international development [1] Group 2 - After listing in Hong Kong, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated-driven industrial upgrades, combining its R&D capabilities with the nationwide sales network of Dongyangguang Changjiang Pharmaceutical [2] - The company focuses on drug research, production, and commercialization, specializing in innovative drugs, including improved new drugs, generic drugs, and biosimilars, with a strategic focus on infection, chronic diseases, and oncology [2] - Dongyangguang Pharmaceutical aims to establish a global operational platform and is committed to becoming a first-class international innovative pharmaceutical company [2]

Group 1 - Dongyangguang Pharmaceutical has completed its last trading day and officially launched the first case of "H-share absorption merger privatization + introduction listing" in the Hong Kong market [1] - The company plans to list on the Hong Kong Stock Exchange on August 7 under the name "Dongyangguang Pharmaceutical" (06887), creating a new paradigm for asset securitization in Chinese innovative pharmaceutical companies [1] - The absorption merger allows Dongyangguang Pharmaceutical to issue H-shares to minority shareholders of its subsidiary Dongyangguang Changjiang Pharmaceutical, facilitating overall listing [1] Group 2 - Industry insiders note that this move breaks traditional capital operation time barriers, reduces friction costs in acquisitions, and effectively safeguards shareholder rights [1] - The listing is seen as a response to the national strategy of optimizing capital market structure and provides a reference model for industrial integration and international development [1] - After the listing, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated industry upgrades, creating a closed loop of "research and development - production - sales" [1][2] Group 3 - Dongyangguang Pharmaceutical is engaged in drug research, production, and commercialization, focusing on innovative drugs, including modified new drugs, generic drugs, and biosimilars [2] - The company adheres to principles of innovation, internationalization, and sustainability, with a strategic focus on treating infections, chronic diseases, and tumors [2] - Dongyangguang Pharmaceutical aims to become a world-class innovative pharmaceutical company with a mature and well-circulated business model [2]

7月29日，东阳光（600673）长江药业完成最后一个交易日，正式启动港股市场首例"H股吸收合并私有 化+介绍上市"的创新资本运作。按计划，公司将于8月7日以"东阳光药"(股票代码：06887.HK)为主体登 陆港交所主板，开创中国创新药企资产证券化新范式。 东阳光药吸收合并港股上市子公司东阳光长江药业实现整体上市，即拟上市主体东阳光药提交H股上市 申请，向其控股子公司东阳光长江药业小股东发行H股，换取前述小股东所持上市公司东阳光长江药业 股份。吸收合并完成后，东阳光药再通过介绍方式实现上市。 业内人士指出，此举不仅打破了传统资本运作方式的时间壁垒，降低企业收购产生的资金摩擦成本，实 现了资源整合与资本升级衔接，还能有效保证股东权益，为产业整合与国际化发展提供了可借鉴范例， 也是积极响应国家"优化资本市场结构"决策部署的生动体现。 东阳光药相关负责人表示，赴港上市后，东阳光药将获得长线资本支持，并有望实现一体化驱动完成产 业升级，即东阳光药研发能力、研发管线将与东阳光长江药业覆盖全国的销售网络形成合力，形成"研 发——生产——销售"闭环，打造全球化运营平台。 资料显示，东阳光药是一家从事药物的研发、生产和商业 ...

人民财讯7月30日电，企查查APP显示，近日，乳源瑶族自治县东阳光（600673）新宙邦（300037）电 子材料有限公司成立，注册资本8000万元，经营范围包含：电子专用材料制造；电子专用材料销售；电 子专用材料研发等。企查查股权穿透显示，该公司由新宙邦等共同持股。 ...

人民财讯7月30日电，深交所公告，因恒生综合小型股指数实施成份股调整，港股通标的证券名单发生 调整并自2025年7月30日起生效，调出东阳光（600673）长江药业。 ...